PIPELINE

In a partnership with SARomics Biostructures, we exploring new small molecule drug candidates for undisclosed MM targets. The drug discovery program targets highly promising candidates with optimal biological characteristics and significant druggability potential.

In a partnership with Sprint Bioscience, we are validating optimal therapeutic targets for AML using our target identification platform and their expertise in fragment-based drug discovery, effective in identifying and developing small molecule drugs.

In a still undisclosed partnership, we explore new AI designed peptides as  drug candidates for undisclosed AML/MM targets.

Multiple myeloma

With an aim to address the challenges posed by multiple myeloma, we have identified 25 promising target candidates for intensive validation. Notably, these candidates exhibit essentiality in multiple myeloma cells while sparing normal cells.

Pancreatic cancer

Pancreatic cancer boasts the highest mortality rate among all cancers, with a mere 12% survival rate over five years. In response to this formidable challenge, we have developed patient-derived in vitro and in vivo model systems and identified more than 20 optimal candidate targets.

Glioblastoma multiforme

The devastating impact of glioblastoma multiforme demands urgent attention. In our research on this lethal brain cancer, we have identified 25 promising candidates slated for rigorous validation using patient-derived cancer cells and advanced animal models.

Ovarian cancer

Ovarian cancer stands as the leading cause of mortality among women with gynecological cancers. In 2022, over 313,000 new cases and 207,000 deaths were reported. In our efforts, we have identified a set of highly promising target candidates, and we’ve established clinically relevant model systems for further exploration.

Acute lymphoblastic leukemia (ALL)

ALL urgently requires effective treatments due to its rapid progression. Key challenges include minimizing treatment toxicity, overcoming drug resistance, and managing high relapse rates. We have identified a set of very promising targets that will soon undergo pharmacological and functional validation in patient samples.

Secondary bone cancer

Secondary bone cancer is an advanced and challenging form of cancer, often associated with a poor prognosis and considered incurable. In response to this pressing medical need, we have identified 30 promising candidate targets. These targets will undergo rigorous functional and pharmacological validation in state-of-the-art model systems specifically designed for this disease.